Newleos Therapeutics

Newleos Therapeutics is a clinical stage neuroscience company co-founded by Longwood Fund and experienced leaders in CNS drug development. The company focuses on developing oral small molecules targeting novel mechanisms for a range of indications, including generalized anxiety, social anxiety, substance use disorders, and cognitive impairment. Newleos operates in the pharmaceutical and biotechnology market, primarily serving patients with central nervous system disorders. The business model involves advancing its clinical pipeline, which was in-licensed from Roche, through various stages of clinical trials to achieve regulatory approval and commercialization. Revenue generation is anticipated through the successful development and eventual market introduction of its drug candidates. Key products in development include NTX 1955, a first-in-class positive allosteric modulator of the GABAA receptor, and NTX 1472, a highly selective vasopressin 1a receptor antagonist. These compounds aim to address the limitations of current therapies by offering targeted treatment options with potentially fewer side effects. Newleos is committed to addressing unmet needs in the management of anxiety and cognitive disorders, leveraging its expertise in neuroscience and drug development.

Keywords: neuroscience, CNS disorders, anxiety treatment, cognitive impairment, drug development, clinical trials, GABAA receptor, vasopressin antagonist, Longwood Fund, Roche.